iBio (IBIO) awards 146,000 stock options to Chief Legal Officer Marc Banjak

Rhea-AI Filing Summary

iBio, Inc. reported that its Chief Legal Officer, Marc Banjak, received a grant of stock options on January 28, 2026. The award covers 146,000 stock options with an exercise price of $2.23 per share, all held directly.

According to the vesting terms, 25% of the common stock underlying these options will vest on the one-year anniversary of the grant date. The remaining options will then vest in equal quarterly installments over the following 36 months, so long as Banjak remains employed by iBio.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Banjak Marc

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	146,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 146,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Banjak Marc

(Last) (First) (Middle)

C/O IBIO, INC.,

11750 SORRENTO VALLEY ROAD, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
iBio, Inc. [ IBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)(1)	$2.23	01/28/2026		A		146,000		01/28/2027	01/27/2036	Common Stock	146,000	$0	146,000	D

Explanation of Responses:

1. These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.

	/s/ Marc Banjak	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did iBio (IBIO) disclose for Marc Banjak?

iBio disclosed that Chief Legal Officer Marc Banjak received a grant of 146,000 stock options on January 28, 2026. These derivative securities give him the right to buy iBio common stock at a fixed exercise price, subject to a multi-year vesting schedule.

What are the key terms of Marc Banjak’s 146,000 iBio stock options?

The grant consists of 146,000 stock options with an exercise price of $2.23 per share. The options cost $0 at grant and are held directly, giving Banjak the right to purchase iBio common shares if and when the options vest and are exercised.

How do Marc Banjak’s iBio stock options vest over time?

The options vest in stages: 25% of the underlying common shares vest on the one-year anniversary of the January 28, 2026 grant. The remaining 75% then vest in equal quarterly installments over the next 36 months, contingent on his continued employment with iBio.

How many iBio derivative securities does Marc Banjak hold after this Form 4?

Following the reported transaction, Marc Banjak beneficially owns 146,000 derivative securities in the form of stock options. All of these options are reported as directly owned, tied to the vesting schedule disclosed in the filing’s explanatory footnote.

What does this Form 4 reveal about iBio executive compensation?

The filing shows that iBio granted its Chief Legal Officer stock options as part of his compensation structure. The 146,000 options with time-based vesting and a $2.23 exercise price indicate equity incentives linked to his continued employment and potential future share ownership.